Compare ASMB & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASMB | TCPC |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 407.2M |
| IPO Year | 2010 | 2006 |
| Metric | ASMB | TCPC |
|---|---|---|
| Price | $28.97 | $3.55 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 2 |
| Target Price | ★ $43.40 | $3.50 |
| AVG Volume (30 Days) | 62.5K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 21.47% |
| EPS Growth | ★ 91.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $274.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.76 | $3.44 |
| 52 Week High | $39.71 | $8.05 |
| Indicator | ASMB | TCPC |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 37.43 |
| Support Level | $26.71 | N/A |
| Resistance Level | $30.54 | $3.75 |
| Average True Range (ATR) | 1.45 | 0.14 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 64.01 | 42.86 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.